<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02975557</url>
  </required_header>
  <id_info>
    <org_study_id>UIC-CNBL-2002</org_study_id>
    <nct_id>NCT02975557</nct_id>
  </id_info>
  <brief_title>Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)</brief_title>
  <official_title>A Phase I/II Randomized, Placebo-Controlled, Double-Blind, Single-Center, Tolerability And Preliminary Efficacy Study Of Use of Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to establish whether patients with dry eye disease (DED) are
      able to tolerate receiving Brimonidine: 0.15% eye drops two times a day for twelve weeks
      (primary tolerability objective) and to investigate the preliminary efficacy of Brimonidine
      0.15% topical eye drop solution in treating MGD (primary efficacy objective).

      Meibomian Gland dysfunction can happen with numerous conditions such as Rosacea, Sjögren's
      syndrome, and oGVHD. In order to limit the influence of differing etiologies on the outcome
      of this trial, the investigator has limited the screening to MGD that accompanies oGVHD.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual of subjects. May take longer than expected to complete the trial.
  </why_stopped>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">March 28, 2017</completion_date>
  <primary_completion_date type="Actual">March 28, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean reduction in OSDI (Ocular Surface Disease Index) score</measure>
    <time_frame>Between baseline and 12 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in ocular surface/lid margin staining score as measured by Rose Bengal/Fluorescein dye staining</measure>
    <time_frame>Between baseline and 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tear secretion as measured by Schirmer I test</measure>
    <time_frame>Between baseline and 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Keratograph Ocular Bulbar Redness Score</measure>
    <time_frame>Between baseline, 3 Weeks, 6 Weeks, 9 Weeks, and 12 Weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lid margin vascularization/telangiectasia</measure>
    <time_frame>Between baseline, 3 Weeks, 6 Weeks, 9 Weeks, 12 Weeks, and 15 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression (CGI) of change in symptoms from baseline (physician's rating)</measure>
    <time_frame>Between 3 Weeks, 6 Weeks, 9 Weeks, 12 Weeks, and 15 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Global Assessment (SGA) of overall change from baseline (subject's rating)</measure>
    <time_frame>Between baseline and 3 Weeks, 6 Weeks, 9 Weeks, 12 Weeks, 15 Weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of visible meibomian gland orifices, and alteration (capping/ obliteration) of the orifices</measure>
    <time_frame>Baseline, 3 Weeks, 6 Weeks, 9 Weeks, and 12 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Meibum expression</measure>
    <time_frame>Baseline, 3 Weeks, 6 Weeks, 9 Weeks, 12 Weeks, and 15 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quality of expressed meibum</measure>
    <time_frame>Baseline, 3 Weeks, 6 Weeks, 9 Weeks, 12 Weeks, and 15 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Eyelid margin changes- thickening, hyperkeratinization, irregularity and muco-cutaneous junction shift</measure>
    <time_frame>Between baseline, 3 Weeks, 6 Weeks, 9 Weeks, 12 Weeks, and 15 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Ocular surface redness score</measure>
    <time_frame>Baseline, 3 Weeks, 6 Weeks, 9 Weeks, 12 Weeks, and 15 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Non-Invasive Keratograph Tear Break-Up Time</measure>
    <time_frame>Between baseline, 3 Weeks, 6 Weeks, 9 Weeks, and 12 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Tear Meniscus Height</measure>
    <time_frame>Between baseline, 3 Weeks, 6 Weeks, 9 Weeks, and 12 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Tear Fluid Osmolarity</measure>
    <time_frame>Between baseline, 6 Weeks and 12 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Lipid Layer Thickness</measure>
    <time_frame>Between baseline, 6 Weeks and 12 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Meibomian Gland Drop-Out</measure>
    <time_frame>Between baseline, 6 Weeks and 12 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in partial or complete blink</measure>
    <time_frame>Between baseline, 6 Weeks and 12 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in frequency of blinks</measure>
    <time_frame>Between baseline, 6 Weeks and 12 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Visual acuity change</measure>
    <time_frame>Between baseline, 3 Weeks, 6 Weeks, 9 Weeks, 12 Weeks, and 15 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in frequency of administration of artificial tears or concomitant eye drops</measure>
    <time_frame>Between baseline, 3 Weeks, 6 Weeks, 9 Weeks, 12 Weeks, and 15 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Measurement of number and type of cells (particularly leukocytes) in tear film</measure>
    <time_frame>Baseline, 3 Weeks, 6 Weeks, 9 Weeks, and 12 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The change in the test substance tolerance</measure>
    <time_frame>Between Day 1 (post-dose) and at weeks 3, 6, 9 and 12</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Dry Eye</condition>
  <condition>Ocular Graft vs Host Disease</condition>
  <condition>Meibomian Gland Dysfunction</condition>
  <arm_group>
    <arm_group_label>Brimonidine 0.15%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Brimonidine 0.15% eye drops 2 times a day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brimonidine 0.075%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Brimonidine 0.075% (1:1 dilution will be performed using 0.15% Alphagan-P solution with Refresh Plus Artificial Tears solution) eye drops 2 times a day for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (Refresh plus Artificial Tear) dispensed in Brimonidine bottles 2 times a day for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brimonidine 0.15%</intervention_name>
    <description>Brimonidine 0.15% eye drops 2 times a day for 12 weeks</description>
    <arm_group_label>Brimonidine 0.15%</arm_group_label>
    <other_name>Alphagan P</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brimonidine 0.075%</intervention_name>
    <description>Brimonidine 0.075% (1:1 dilution will be performed using 0.15% Alphagan-P solution with Refresh Plus Artificial Tears solution) eye drops 2 times a day for 12 weeks.</description>
    <arm_group_label>Brimonidine 0.075%</arm_group_label>
    <other_name>Alphagan P</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (Refresh plus Artificial Tear) dispensed in Brimonidine bottles 2 times a day for 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Refresh plus Artificial Tear</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 18 years or older.

          2. Capable of giving informed consent and does provide informed consent.

          3. Diagnosis of Meibomian Gland Disease

          4. Women must be post-menopausal ≥ 1 year, or surgically sterilized. If not, a negative
             urine pregnancy test is required within 7 days of the participant receiving first dose
             of study drug along with definite evidence of contraceptive use during the duration of
             the study. Women of reproductive age should use a method of birth control that is
             acceptable to the participant and the study doctor. This may include oral
             contraceptive pills, birth control implants, barrier methods or abstinence. If a
             participant suspects pregnancy after being enrolled, another pregnancy test will be
             administered. If the test is positive, the participant will be discontinued from the
             study immediately.

        Exclusion Criteria:

          1. Allergic to Brimonidine or any similar products, or excipients of Brimonidine

          2. Currently receiving any Brimonidine preparation as a part of glaucoma management

          3. Receiving or have received within 30 days any experimental systemic medication.

          4. Active ocular infection or ocular allergies.

          5. Any history of eyelid surgery or ocular surgery within the past 3 months.

          6. Corneal epithelial defect larger than 1 mm2 in either eye.

          7. Have active drug/alcohol dependence or abuse history.

          8. Vulnerable populations, such as neonates, pregnant women, children, prisoners,
             institutionalized individuals, or others who may be considered vulnerable populations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandeep Jain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Illinois Eye and Ear Infirmary, University of Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Translational Clinic of Corneal Neurobiology Laboratory, Illinois Eye and Ear Infirmary, University of Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://chicago.medicine.uic.edu/directory/name/sandeep-jain-md-jain/</url>
    <description>Principal Investigator description</description>
  </link>
  <link>
    <url>http://eyecare.uic.edu/clinics/DryEyeandOcularGVHDclinic.shtml</url>
    <description>Dry Eye and ocular GVHD Clinic at UIC</description>
  </link>
  <link>
    <url>http://cornealneurobiology.uic.edu/</url>
    <description>Corneal Neurobiology Laboratory (National Eye Institute funded)</description>
  </link>
  <reference>
    <citation>Tibrewal S, Sarkar J, Jassim SH, Gandhi S, Sonawane S, Chaudhary S, Byun YS, Ivanir Y, Hallak J, Horner JH, Newcomb M, Jain S. Tear fluid extracellular DNA: diagnostic and therapeutic implications in dry eye disease. Invest Ophthalmol Vis Sci. 2013 Dec 11;54(13):8051-61. doi: 10.1167/iovs.13-12844.</citation>
    <PMID>24255046</PMID>
  </reference>
  <reference>
    <citation>Sonawane S, Khanolkar V, Namavari A, Chaudhary S, Gandhi S, Tibrewal S, Jassim SH, Shaheen B, Hallak J, Horner JH, Newcomb M, Sarkar J, Jain S. Ocular surface extracellular DNA and nuclease activity imbalance: a new paradigm for inflammation in dry eye disease. Invest Ophthalmol Vis Sci. 2012 Dec 17;53(13):8253-63. doi: 10.1167/iovs.12-10430.</citation>
    <PMID>23169882</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2016</study_first_submitted>
  <study_first_submitted_qc>November 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2016</study_first_posted>
  <last_update_submitted>November 27, 2017</last_update_submitted>
  <last_update_submitted_qc>November 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Sandeep Jain</investigator_full_name>
    <investigator_title>Associate Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Brimonidine</keyword>
  <keyword>Dry Eye</keyword>
  <keyword>oGVHD</keyword>
  <keyword>MGD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Brimonidine Tartrate</mesh_term>
    <mesh_term>Lubricant Eye Drops</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

